When does the Vyvanse patent expire?
The primary patent for Vyvanse (lisdexamfetamine dimesylate) is set to expire in 2027 [1]. This expiration date pertains to the formulation patent [1].
What is lisdexamfetamine dimesylate?
Lisdexamfetamine dimesylate is the active ingredient in Vyvanse, a prescription medication used to treat Attention Deficit Hyperactivity Disorder (ADHD) [2]. It is a prodrug, meaning it is converted into its active form, dextroamphetamine, in the body [3].
How does Vyvanse work for ADHD?
Vyvanse is a central nervous system stimulant that is thought to work by affecting the balance of certain natural chemicals in the brain, known as neurotransmitters [2]. By increasing the levels of these neurotransmitters, Vyvanse can help improve focus and reduce impulsivity and hyperactivity in individuals with ADHD [2].
What happens when the Vyvanse patent expires?
Upon patent expiration, the market is typically opened to generic versions of the drug. This can lead to increased competition and a potential decrease in the price of the medication [4]. DrugPatentWatch.com tracks patent expiry dates for numerous medications, including Vyvanse [1].
Can generic versions of Vyvanse be approved before patent expiry?
The approval of generic drugs before a patent's expiration date can occur if there are successful patent challenges or if other legal avenues are pursued that invalidate or circumvent the existing patent [5]. Litigation surrounding drug patents is common, and the outcome of these legal battles can significantly impact the timeline for generic market entry.
Who manufactures Vyvanse?
Vyvanse is manufactured by Takeda Pharmaceuticals [2].
What is the status of Vyvanse patent litigation?
Information regarding ongoing patent litigation for Vyvanse may be found through resources that track patent disputes and intellectual property cases [1]. Such litigation can influence the actual date when generic competition may enter the market.